22 - Introduction to Joint Disease Flashcards

1
Q

What does mono, poly, and oligo mean in terms of joints?

A

Mono: one

Poly: 4 or more

Oligo: 2-3 joints (“pauci”)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the parts of the axial skeleton?

A

Skull, mandible, sternum, ribs, vertebral column, and sacrum.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe the hyaline cartilage of a synovial joint (diarthrodial joint)?

A

Hyaline cartilage on articular surface: for elastic shock absorber, spreads weight acress joint surface. Friction free.

  • avascular, type II collagen, water, proteoglycans, and chondrocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the synovial cavity of a synovial joint (diarthrodial joints)?

A

Synovial cells line synovial cavity: cuboidal cells (1-4 layers thick)

  • make synovial fluid, remove debris, regulate movement of solutes, electrolytes and proteins from capillaries into fluid.
  • NOT present over articular cartilage

Synovial fluid: viscous filtrate of plasma containing hyaluronic acid as a lubricant/provides nutrients to articular cartilage.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What would a normal femoral head look like grossly? What about on histology of the synovium and articular cartilage?

A

Blue/white shiney-ish appearance.

Articular cartilage: multiple layers of chondrocytes within the cartilage.

Synovium: under cuboidal cells are vessels and fibrous tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the six different patterns of arthritis?

A
  1. Inflamm vs non-inflamm
  2. Monoarthritis vs oligo vs polyarthritis
  3. Acute vs chronic
  4. Large joint vs small joint involvement
  5. Symmetric vs asymmetric
  6. Axial vs peripheral
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What labratory testing would you do to identify arthritis?

A

1. “generic” markers of inflammation:

  • Sed Rate
  • CRP
  • Anemia
  • Leukocytosis (high WBC)

2. Serology: presence of autoantibodies: Rheumatoid factor, CCP antibody, antinuclear antigen (ANA).

3. Synovial joint fluid analysis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What can Sed rate elevation result from? What can falsely elevate ESR? How do you adjust for age?

A

Infection (most common), malignancy, and autoimmune/inflamm conditions.

False elevation: end stage renal disease, anemia (fewer RBCs to bump each other to slow decent), obesity, and age.

Women: age + 10/2 = adjusted upper limit of normal

Men: age/2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What an decrease ESR?

A
  • Low fibrogen (DIC)
  • Polycythenia vera
  • Sickle cell
  • Spherocytosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is C-reactive protein? Where are they made and what do very high CRP levels indicate? What can be done to detect it?

A

Molecule binds dying cells/pathogens: Rapid ride in hours of tissue injury. Synthesized in liver.

Very high CRP suggests bacterial infection

High sensitivity CRP (hsCRP) measures CRP but can detect it in lower concentrations. Elevation linked to increased CV disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is rheumatoid factor? What is anti-cyclic citrullinated peptide antibody (CCP)? What is each sensitive/specific for?

A

Rheumatoid factor: autoantibody that binds Fc of human IgG (70% sensitive for RA, 80% specific for RA).

  • False + : chronic HepC, sjogrens, primary biliary cirrhosis, multiple myeloma, and ~4% of normal pop.

Anti-cyclic citrullinated peptide Ab (CCP): 70% sensitive for RA, >90% specific for RA.

These are both found on serology.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do doctors look for ANA? What are the different types and what diseases are they associated with?

A

Immunofluorescence.

dsDNA - SLE

SSA (RO) - sjogrens, SLE

Smith - SLE

RNP - missed connective tissue disease (MCTD)

Scl-70 - scleromerma

Jo-1 - inflamm. myopathy

Histone - drug induced lupus

Not great because there’s MANY false positive results.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Inflammation causes synovial fluid to become _____ in character.

A

Less viscous - so it drips like water instead of showing a normal string sign

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What WBC/mm^3 is seen in normal, non-inflamm, inflammatory, septic, and hemorrhagic synovial fluid?

A

Normal: <200

Non-inflamm: 200-2,000

Inflammatory: 2,000-10,000 (up to 100,000)

Septic: >80,000

Hemorrhagic: 200-2,000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is gout? When it is more common?

A

Very inflamm. arthritis linked to metabolic disorder causing ^ in blood uric acid (hyperuricemia) and pro-inflamm crystals in the joint.

  • in an acute attack uric acid levels may be falsely low (DO NOT CHECK SERUM LEVELS - IT IS NOT AN INDICATION OF GOUT).

More common with increased BMI. Somewhat more common in men, but increases in women post-menopause.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the two causes of hyperuricemia (increased uric acid in blood)?

A

10% overproduction

90% caused by underexcretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the clinical presentation of acute gout?

A
  • Abrupt obset of severe pain
  • Usually monoarticular and in lower extremity
  • Exam shows synovitis with redness, swelling,and extreme tenderness over join.

Self-limited and resolves in 8-10 days if left untreated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the clinical presentation of chronic gout?

A

Polyarticular pattern and can be destructive.

Tophaceous pattern - nodular masses of uric acid in soft tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How would you detect gout?

A

Fluid aspiration: look for monosodium urate needle-shaped crystals.

They will be yellow and parall and negetively birefringement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is chronic tophaceous arthritis?

A

Repetitive episodes of gout, urates encrust articular surfaces and form depossits that destory cartilage.

Tophi are large aggreggates of urate crystals surrounded by lymphocytes, giant cells, and fibroblasts.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are therapeutic goals when treating gout?

A
  • Increased excretion of uric acid
  • Inhibit inflamm cells
  • Inhibit uric acid biosyn
  • Produce symptom releif (NSAIDs or steroids short term)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

When should NSAIDs be given to someone with gout? What are some examples? What are some things that need to be considered?

A

Within the first 24hrs; indomethacin or naproxen

DO NOT GIVE ASPIRIN

Contraindicitons: GI, platelet, renal, and hypersensitivity effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Why shouldnt aspirins/salicylates be given to someone with gout?

A

Most urate is reabsorbed but a small secretory component in the tubule occurs and can be reabsorbed.

Aspirin blocks secretory components and thus decreases excretion - - > increase its presence in blood

Large doses increase excretion because it blocks transport.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

How can corticosteroids be used to treat someone with gout?

A

Symptomas relief in pts that can’t take NSAIDs.

Short term use only.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What is the MOA for Colchicine? How is it given and what are some considerations when giving it?

A

ORAL antimitotic that treats acute gout attacks by binding to mts in inflammatory cells (PMNs) and ultimately inhibits activation and migration.

Can also be used prophylactically in pts with chronic gout.

Metabolized by CYP450; substrate for P-glycoprotein (pump that gets rid of drugs) - ie dont give to pts taking other cyp metabolized drugs or P-gp inhibitors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What are adverse effects of colchicine?

A

Significant!

GI effects: nausea, vomiting, diarrhea, and abd. pain

Greatly limits use of the drug.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What non-pharmacological measures can be used to prevent gout?

A

Abstain from alcohol

Weight loss

Discontinue medicines that impair uric acid excreteion such as aspirin and thiazide diuretics.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are some potential drug therapies to prevent gout flare and destructive effects on joints/kidneys?

A
  1. Allopurinol
  2. Febuxostate
  3. Probenecid
  4. Pegloticase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What is the MOA for allopurinol? What are some adverse effects?

A

Prodrug that prevents chronic gout by blocking xanthine oxidase, which causes plasma uric acid concentration to decrease and urid acid crystals to dissolve.

Hypersensitivity an d acute goet attack may occur due to mobilization of tissue stores of uric acid.

30
Q

What newer drug has a similar MOA to allopurinol? How do the two drugs compare?

A

Febuxostat - non-purine xanthine oxidase inhibitor.

  • more potent (less is neededd) but same efficacy
  • more effective in pts with impaired renal function

Incidence of adverse effects similar to those with allopurinol.

Incidence of CV effects was HIGHER with febuxostat than allopurinol.

31
Q

What is the MOA of Pegloticase? What are some adverse effects?

A

Recombinant form of urate-oxidase enzyme (uricase) used to prevent chronic gout attacks by converting uric acid to an inactive and water soluble metabolite.

Infusion site rxns, gout flare (need to provide prophylaxis for acute gout flares), and immune response b/c the portion of the molecule is foreign.

32
Q

What is the MOA of probenecic? What are some condierations?

A

Uricosuric agent - increases uric acid excretion by competing with renal tubular acid transporter so that less urate is reabsorbed.

  • OAT (oragnic acid transporter), aka URATI

GI side effects; inaffective in pts with renal insufficiency or those with uric acid kidney stones.

33
Q

What are the major drug interactions of gout medication?

A
34
Q

What is rheumatoid arthritis? Who is more likely to get it?

A

Inflamm symmetrical chronic polyarthritis

  • Immune disease involv. both T and B cells
  • Genetic predisposition (HLA-DR4 and HLA-DR1)
  • First degree relatives have a 1.5x higher risk

1% worldwide. Women>Men 2.5:1

35
Q

What is the pathogenesis of RA?

A
  1. APC phagocytose antigens and present to T cells
  2. Activated T cells stim. production of B and T cells
  3. B cells produce plasma cells that form Rheum. antibodies
  4. Helper Tcells activate macrohpages and CD8 T cells
  5. T cells, macrophages, and CD8 cells make TNFa, IL-1, and IL6, and prostaglandins that cause joint inflamm, synovial prolif, and bone and cartilage destruction.
36
Q

What is the cliinical presentation of RA?

A

Gradual onset of joint pain, swelling, and inflammation present for greater than 6 weeks.

Symmetrical, often small joints.

Morning stiffness >1 hr

Elevated inflamm markers and abnormal serology.

37
Q

What are some extra-articular manifestations of RA?

A
  • Vasculitis
  • Interstitial lung disease
  • Premature coronary artery disease
  • Secondary sjogrens syndrome
  • Felty’s syndrome (big spleen, low WBC)
38
Q

What is the pathology of RA?

A

Chronic papillary synovitis: chronic inflamm of the synovium; accompanied by synovial cell hyperplasia that results in pappillary pattern on surface of synovium.

PMNs and fibrin on joint surfaces in acute phase.

Hyperplastic inflammed synovium extends over the articular surface surface, forming a pannus which fills the joint space.

39
Q

What is this an image of?

A

Lymphoid follicles in papillary synovitis (arrows are pointing to papillary structures)in rheumatoid arthritis.

40
Q

What syptes of cells are present in RA?

A

Hyperplastic synovial cells and lymphocytes.

Synovium demonstrates papillary hyperplasia caused by dense inflamm infiltrate.

41
Q

Where do rheumatoid nodules occur? What do they look like grossly and on histology? What causes them?

A

Usually skin(subQ), in areas exposed to pressure (extensor of forearm/elbow). Occurs in ~25% of those with severe disease.

Grossly: non tender firm, round, oval

Hist.: central zone of fibrinoid necrosis surrounded by rim of epithelioid histiocytes, and then lymphocytes and plasma cells.

Necrosis secondary to vascular damage

42
Q

What are the therapeutic goals of treating RA?

A
  • Relieve pain
  • Reduce inflamm
  • Slow down or stop joint damage
  • Improve a person’s sense of well-being and ability to function
43
Q

What effect do NSAIDs have on RA? How are they given?

A

Large doses, long duration of treatment. No effect on progression of disease. Relieve symptoms of pain.

44
Q

What are biologic resposne modifiers?

A

Biologics are a class of drugs which includes monoclonal antibodies, receptor analogues, and chimeric small molecules designed to bind to or mimic their molecular target.

45
Q

What is the admin, distribution, and half life of antibodies and most biologics used to treat RA? What aresome adverse effects?

A

Admin: subQ - 24-95% F, intraM - safe F, IV 100% F

Distribution: extracellular, do not cross BBB

~21 day half life (infreq admin)

Adverse effects: generation of endogenous Ab against therapeutic Ab, increased risk for infections (all RA drugs).

46
Q

What is the MOA of Etanercept (enbrel)? What is the half life, adverse effects, and therapetuic indications?

A

Inhibits ability of soluble TNFa to bind its receptor (TNFa is a pre-inflamm cytokine).

Long half-life.

Injection-site reactions and infections.

Indicated in mod-severe RA, juvenile RA, and early stage.

47
Q

What is the MOA of Adalimumab (humira)? What is the half life, adverse effects, and therapetuic indications?

A

Binds soluble AND transmembrane forms of TNFa to prevent TNFa binding to its receptor.

Long half life.

Injection site rxns and infections.

Mod-severe RA, active mod-severe juvenile arthritis, may be used alone or with methotrexate.

48
Q

What is the MOA of Tocilizumab (actemra)? What is the half life, adverse effects, and therapetuic indications?

A

Binds to soluble AND membrane-bound IL-6 receptors and inhibits IL-6 ediated signaling. (IL-6 activates T and B cells, macrophages, and osteoclasts and mediates hepatic acute phase response).

Long half life.

Injection site reaction, increased risk of infections, alteration in lipid profile.

Adult pts with mod-severe active RA who have inadequate resposne to one or more TNF antagonist.

49
Q

What is the MOA of Tofacitinib (Xeljanz)? What is the admin, adverse effects, and therapetuic indications?

A

Inhibits janus kinase (JAK).

ORAL admin.

Increased risk of infections, alterations in lipid profile.

Treats mod-severe active RA in pts with inadequate respnose to methotrexate.

50
Q

What is the MOA of rituximab (rituxan)? What is the half life, adverse effects, and therapeutic use?

A

B cell depleting monoclonal anti-CD20 antibody (CD20 normally responds to complement activation).

Long half life

Injection site reactions and inreased risk of infections.

Mod-severe active RA in combo with methotrexate in those with inadequate resposne to one or more anti-TNF aget.

51
Q

What is the MOA of abatacept (orencia)? What is the half life, adverse effects, and therapeutic use?

A

Fusion protein that inhibits the binding to CD28 and prevents the activation of T cells.

Long half life.

Injection site reaction and infections.

Mod-severe active RA in adults with inadequate response to one or more DMARDs or anto-TNF agents.

52
Q

What are some disease modifying anti-rheumatic drugs (DMARDs) that are NOT biologics?

A

Methotrexate, leflunomide, hydroxychloroquine.

53
Q

What is the MOA of methotrexate?

A

Inhibits folate pathway by competitively inhibiting dihydrofolate reductase and preventing the production of tetrahydrofolate.

This ultimately inhibits the prolif and activity of T cells and B cells.

54
Q

How is methotrexate given? What are common toxicities?

A

Oral, IM, subQ

Primarily cleared by kidneys (80-90% unchanged in urine).

Admin as long-term, low-dose therapy.

Life threatening: hepatotoxicity, pulm damage, myelosuppression. Common toxicities: GI nausea, soreness of mouth (stomatosis), rash on extremeties, fatigue, headache.

55
Q

What is the initial treatment of RA?

A
  • Non-biologic DMARD: methotrexate
  • Alternative to monotherapies include other DMARD non-biologics like leflunomide or sulfasalazine or the DMARD biologic, TNFa inhibitors.
  • Symptomatic relief before you get effects of MTX with NSAIDs or steroids.

If no remission, combo therapy is used.

56
Q

What is osteoarthrisis (OA)? Who does it occur in?

A

Progressive, degen. joint disorder caused by gradual losso f cartilage resulting in body spurs at margins and subchondral cysts.

Most common arthritis in adults.

Risk factors: gename, ^ age, obesity, DB, trauma.

57
Q

What is the clinical presentation of OA?

A

Non-inflammatory joint pain

  • worse with activity
  • minites of morning stiffness (as opposed to 1+ hour with RA)
  • brief stiffness after prolonged immobility (gelling)
  • “crunching”
58
Q

How does OA differ from RA?

A

OA: fusiform swelling of joints, heberden’s nodules (boney swellings), DIP joints affected.

RA: swan neck and boutonniere deformitiy, ulnar deviation, DIP joints spared.

59
Q

How would you diagnose OA? What may be seen on radiology?

A

Based on joint distribution, character of pain, and exam findings.

  • blood tests usually not helpful
  • X rays not required (controversial)
  • Synovial fluid aspiration may rule out other arthritis

Xray: narrowing of joint space, osteophytes (bony outgrowth associated with degen of cartilage at joints).

60
Q

What is the pahtogenesis of OA?

A

Imbalance in cytokine gorwth factor activity resulting in matrix loss and degradation (breakdown of normal process)

Likely multiple etiologies. NOT inevitable with age, but mechanism stress and aging are factors.

61
Q

What ist the early pathology of OA?

A

Superficial layers of catilage are destroyed: fibrillation and cracking of the matrix

Limited chondrocyet proliferation and new matrix formation

62
Q

Describethe femoral head in pts with more advaced OA?

A
63
Q

Describe the osteophyte formation seen with OA? Where do they typically occur?

A

Bony outgrowth at margins of articular surface in specific locations; causes increased joint size.

Hip joint: occur all aorund entire joint margin, but typically large flat one occurs on medial surface extending to fovea.

DIP: heberden nodes

PIP: bouchard nodes

64
Q

What is the differene between a RA and OA joint?

A

RA: pannus formation, inflammation

OA: subchondral cyst, bony spur

65
Q

What are some therapies for OA?

A

Weight loss, exercise, and PT

Intra-articualr therapies: corticosteroids, hyaluonans

Topical: capsaicin, salicylates, and menthol

Systemic: acetaminophen, duloxetine, and NSAIDs

66
Q

What is the MOA of capsaicin? How is it given, what are the adverse effects, and what does it treat?

A

Agonist for TRPV1 receptor ion channel - induces release of SubP (mediator of pain from periphery to CNA). After repeated application, it depletes the neuron of SubP and prevents reaccumulation.

Topical; local transient application site pain and erythema.

OTC for minor pain (OA)

67
Q

What is the MOA of duloxetine (cymbalta)? What are side effects and therapeutic uses?

A

Centrally acting oral analgesic; serotonin-norepi reuptake inhibitor. Analgesic effect sooner than anti-depressive effect and at lower doses.

Side effects: nausea, dry mouth, constib=pation.

Therapeutic use: FDA approved for chronic MSK pain

68
Q

What are two symptomatic slow-acting drugs for OA (SYSADOA)? How does each work?

A

Glucosamine sulfate: principle substrate in the biosyn of proteoglycan, essential for maintaining cartilage

Chondroitin sulfate: maintains viscosity in joints, stimulates cartilage repair enzymes, and inhibits enzymes that break down cartilage.

69
Q

Describe the effectiveness of glucosamine and chondroitin in treated OA?

A

Dietary supplements; effectiveness remains to be established.

Safe, but as with other supplements, their potency and purity may vary because they are regulated as food and not as drugs.

70
Q

What is the MOA of hyaluronic acid (HA)? How is it given? what are adverse effects?

A

Injection of polysaccharice made of glucosamine and glucuronic acid:

  • Inhibits inflamm mediators
  • Decreases cartilage degradation
  • Promotes cartilage matrix synthesis

Can cause joint inflammation; small risk of infection. No evidence that it slosw disease progression but may help reduce pain.

71
Q

What is the therapeutic use of hyaluronic acid (HA)?

A

FDA approved for OA of the knee; generally reverved for those who can’t take NSAIDs.

No evidence showing that it slows the progression of the disease.

72
Q

Do opioids help treat OA?

A

No; there’s no high-quality evidence that opioids improve funciton more than nonopioid analgesics.

May be used as a second or third line opteion but should only be used for a short period of time.